Dupilumab (Moderate-Severe Asthma)

Asthma dosing for adults and adolescents 12 years of age and older. For patients with severe asthma who are on oral corticosteroids, for patients with severe asthma and co-morbid moderate-to-severe atopic dermatitis, or for adults with co-morbid severe chronic rhinosinusitis with nasal polyposis, the SPC recommends an initial dose of 600 mg (two 300 mg injections) followed by 300 mg every other week. When an initial 400 mg dose is required, give the two 200 mg injections consecutively at different injection sites; rotate the injection site with each injection. Treatment should be initiated by healthcare professionals experienced in the diagnosis and treatment of the indicated conditions. Missed dose: give within 7 days of the missed every-other-week dose then resume the original schedule; if more than 7 days have passed, wait until the next scheduled dose. Elderly: no dose adjustment. No dose adjustment for body weight in asthma patients 12 years and older. Patients on concomitant oral corticosteroids may reduce their steroid dose gradually once clinical improvement has occurred - corticosteroids must not be stopped abruptly. Dupilumab must not be used to treat acute asthma symptoms, acute exacerbations of asthma or COPD, acute bronchospasm or status asthmaticus. Intended for long-term treatment, with the need for continued therapy considered at least annually. Children 6 to 11 years with asthma are dosed by weight band, not per kg: 15 to less than 30 kg, 300 mg every four weeks; 30 kg to less than 60 kg, 200 mg every other week or 300 mg every four weeks; 60 kg or more, 200 mg every other week. Safety and efficacy in children with severe asthma below 6 years of age have not been established - verify all paediatric use against a children's formulary. Source product: Dupixent 200 mg solution for injection in pre-filled pen. SPC sections 4.4 and 4.8 were truncated at the source-fetch limit and no section 4.5 interactions text was captured.